Full Text View
Tabular View
No Study Results Posted
Related Studies
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
This study has been completed.
Study NCT00210249   Information provided by Institut Bergonié
First Received: September 13, 2005   Last Updated: October 31, 2007   History of Changes

September 13, 2005
October 31, 2007
September 2002
 
 
 
Complete list of historical versions of study NCT00210249 on ClinicalTrials.gov Archive Site
 
 
 
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country.

Number of elderly people over 70 is increasing in France. In 2002, in the south-west, 273,741 of them were over 75 years, i.e. 9.2% of Aquitaine population. Incidence of cancer in this old age is 16,500 new cases per year, more than fifty percent of people with cancer. Treatment modalities of elderly people is one of the 70 priorities of the "Plan cancer" instituted by the French government. They are very few therapeutic trials dedicated. Oncologists hesitate to treat them because they are either afraid of inducing toxicity or of breaking down quality of life. Consequently, we decided to launch a protocol with both oncologists and geriatricians which principal aim is to find out if geriatric assessment data can help to better predict for chemotherapy toxicity, loss of autonomy and survival. We plan to accrue 360 patients diagnosed for cancer, including digestive, pulmonary, prostate, lymphoma, bladder, ovary cancer for whom first-line chemotherapy is planned. Patients are initially classified according to usual methods of medical oncology practice into three groups: patients who can receive standard treatment, reduced standard treatment or treatment adapted to the frail condition. Around Aquitaine, , we organised seven teams composed of one geriatrician and one nurse. Two kind of teams were activated: one which cover ten treatment sites in Bordeaux area and six sedentary teams which worked half a day a week in designated hospitals . Geriatric evaluation included test of cognitive functions (MMS), nutritional status (MNA), co-morbidity (CIRS-G), mobility (Get up and Go), activities (ADL;IADL), quality of life (QLQ-C30), depression (GDS-15) and Lachs-Balducci screening. Patients have four geriatric evaluations : before treatment, day 1 cycle 2, day 1 cycle 4, day 1 cycle 7 and/or end of chemotherapy. Since September 2002, 177 patients have been included, 112 have finished: 47.3% have received four evaluations, 16.1% died before the end of protocol, 14.3% stopped because they were in progression and changed their treatment, 11.6% met administrative problem that didn't allow all evaluations, 7.1% declined after inclusion and 3.6% finished their treatment before. The following results have been obtained: before treatment, 73% of these patients were at risk of undernutrition (MNA< 23.5), about 1/3 had one or more inability or a risk of falls (38% IADL<6, 29% get up and go>20seconds, 27% ADL>1, 34% PS<1), 28% of them had altered cognitive functions (MMS<24), 29% were depressive (GDS-15>6), 25% thought they had poor quality of life (QLQ-C30<4). Protocol will be closed in September 2005.

 
 
Observational
Prospective
  • Lymphoma
  • Digestive System Diseases
  • Ovarian Diseases
  • Pulmonary Disease
  • Prostatic Disease
  • Bladder Disease
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
360
June 2006
 

Inclusion criteria:

  • Age ≥ 70 years
  • First line of chemotherapy
  • Cancer previously mentioned
Both
70 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00210249
 
IB2002-26, ONCOGERIATRIE
Institut Bergonié
  • Sanofi-Synthelabo
  • Aventis Pharmaceuticals
  • Amgen
  • Chugai Pharmaceutical
  • Bristol-Myers Squibb
Principal Investigator: Pierre SOUBEYRAN, MD, PhD Institut Bergonié
Institut Bergonié
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP